External view of Emory Children's Center building

Emory Children’s Center is one of twenty-five type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Andrew Muir, MD, the TrialNet team at Emory is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

 

Our Team

Portrait photo

Andrew Muir, MD

Portrait photo

Leo Panagiotakopoulos, MD

Portrait photo

Eric Felner, MD

Portrait photo

Lori Kwapil

Portrait photo

Wanda Sanchez

Portrait photo

Kelsea Lozada

Portrait photo

Peggy Jenkins, RN

Amber Antich

Research Studies

Risk Screening Risk Screening

If you have a relative with T1D, you may be eligible for risk screening that can detect the early stages of T1D years before symptoms appear. More

Monitoring Monitoring

Depending on your risk screening results, you may be eligible for monitoring. We’ll monitor you for disease progression and let you know if you become eligible for a study. More

Prevention Study Abatacept Prevention Study

TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 or stage 2), and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression. Details

Prevention Study Hydroxychloroquine (HCQ)

We are testing the drug hydroxychloroquine (HCQ) to see if it can delay or prevent early stage T1D (stage 1) from progressing to abnormal glucose tolerance (stage 2) and ultimately prevent clinical diagnosis (stage 3). HCQ is already used to reduce symptoms and progression of other autoimmune diseases, such as rheumatoid arthritis and lupus. This is the first study to see if it can prevent or delay T1D. Details

Long Term Longterm Follow-up

If you are diagnosed with T1D while participating in one of our prevention studies, we’re still here for you. You can continue to receive personal monitoring while helping us learn more. More